Relay Therapeutics, Inc. (NASDAQ: RLAY) is a Healthcare company (Biotechnology) with a market capitalization of $3.6B. The Maz Rating grades it against the other companies in its sector.
Relay Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $16.47, Relay Therapeutics, Inc. trades at 352.9x sales and 4.4x book value. Over the last twelve months it generated about $10M of revenue and a net loss of $332M. It runs a gross margin of 89.3%, an operating margin of -3094.6% and a net margin of -2837.0%. It shows return on equity of -40.2%, return on invested capital of -37.9% and a free cash flow yield of -5.9%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 14.62. Over the past 52 weeks the share price ranged from $6.25 to $21.27, with a beta of 1.74.
Relay Therapeutics, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 1 Strong Buy and 15 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.